A randomized controlled trial to compare the effects of time-restricted eating versus Mediterranean diet on symptoms and quality of life in bipolar disorder.

BACKGROUND: The primary objective of this randomized controlled trial (RCT) is to establish the effectiveness of time-restricted eating (TRE) compared with the Mediterranean diet for people with bipolar disorder (BD) who have symptoms of sleep disorders or circadian rhythm sleep-wake disruption. This work builds on the growing evidence that TRE has benefits for improving circadian rhythms. TRE and Mediterranean diet guidance will be offered remotely using self-help materials and an app, with coaching support. METHODS: This study is an international RCT to compare the effectiveness of TRE and the Mediterranean diet. Three hundred participants will be recruited primarily via social media. Main inclusion criteria are: receiving treatment for a diagnosis of BD I or II (confirmed via DIAMOND structured diagnostic interview), endorsement of sleep or circadian problems, self-reported eating window of ≥ 12 h, and no current mood episode, acute suicidality, eating disorder, psychosis, alcohol or substance use disorder, or other health conditions that would interfere with or limit the safety of following the dietary guidance. Participants will be asked to complete baseline daily food logging for two weeks and then will be randomly allocated to follow TRE or the Mediterranean diet for 8 weeks, during which time, they will continue to complete daily food logging. Intervention content will be delivered via an app. Symptom severity interviews will be conducted at baseline; mid-intervention (4 weeks after the intervention begins); end of intervention; and at 6, 9, and 15 months post-baseline by phone or videoconference. Self-rated symptom severity and quality of life data will be gathered at those timepoints, as well as at 16 weeks post baseline. To provide a more refined index of whether TRE successfully decreases emotional lability and improves sleep, participants will be asked to complete a sleep diary (core CSD) each morning and complete six mood assessments per day for eight days at baseline and again at mid-intervention. DISCUSSION: The planned research will provide novel and important information on whether TRE is more beneficial than the Mediterranean diet for reducing mood symptoms and improving quality of life in individuals with BD who also experience sleep or circadian problems. TRIAL REGISTRATION: ClinicalTrials.gov ID NCT06188754.

Synthesis of Chitosan-Silver Nanocomposite and Its Evaluation as an Antibacterial Coating for Mobile Phone Glass Protectors.

An easy and environment-friendly route for antibacterial coating suited for mobile phone glass protectors was successfully demonstrated. In this route, freshly prepared chitosan solution in 1% v/v acetic acid was added with 0.1 M silver nitrate solution and 0.1 M sodium hydroxide solution and incubated with agitation at 70 °C to form chitosan-silver nanoparticles (ChAgNPs). Varied concentrations of chitosan solution (i.e., 0.1, 0.2, 0.4, 0.6, and 0.8% w/v) were used to investigate its particle size, size distribution, and later on, its antibacterial activity. Transmission electron microscope (TEM) imaging revealed that the smallest average diameter of silver nanoparticles (AgNPs) was 13.04 nm from 0.8% w/v chitosan solution. Further characterizations of the optimal nanocomposite formulation using UV-vis spectroscopy and Fourier transfer infrared spectroscopy were also performed. Using a dynamic light scattering zetasizer, the average ζ-potential of the optimal ChAgNP formulation was at +56.07 mV, showing high aggregative stability and an average ChAgNP size of 182.37 nm. The ChAgNP nanocoating on glass protectors shows antibacterial activity against Escherichia coli (E. coli) at 24 and 48 h of contact. However, the antibacterial activity decreased from 49.80% (24 h) to 32.60% (48 h).